Site Editor

William J. Gradishar, MD, FACP, FASCO


Outcomes With Sacituzumab Govitecan by Trop-2 Expression in Metastatic Breast Cancer

By: Julia Fiederlein Cipriano
Posted: Thursday, January 19, 2023

Patients with pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer appeared to derive a progression-free survival benefit from treatment with sacituzumab govitecan-hziy versus chemotherapy, regardless of Trop-2 expression, according to Hope S. Rugo, MD, FASCO, of the University of California, San Francisco, and colleagues. The post hoc analysis of the phase III TROPiCS-02 trial, which was presented during the 2022 San Antonio Breast Cancer Symposium (SABCS; Abstract GS5-11), reinforces that Trop-2 testing is not required to receive this antibody-drug conjugate.

In this trial, patients who experienced disease progression with endocrine-based therapies and at least two chemotherapies were randomly assigned to receive sacituzumab govitecan (n = 272; Trop-2–evaluable: n = 238) or physician’s choice of chemotherapy with eribulin, gemcitabine, capecitabine, or vinorelbine (n = 271; Trop-2–evaluable: n = 224). Membrane Trop-2 expression was assessed by immunohistochemistry and expressed as a histochemical score (H-score).

The median durations of progression-free survival with sacituzumab govitecan and chemotherapy were 5.3 and 4.0 months in patients with an H-score of less than 100 (hazard ratio [HR] = 0.77) and 6.4 and 4.1 months in those with an H-score of at least 100 (HR = 0.60); the median durations of overall survival were 14.6 versus 11.3 months (HR = 0.75) and 14.4 versus 11.2 months (HR = 0.83), respectively. Disease response was observed in the 34 patients with an H-score of up to 10 who were treated with sacituzumab govitecan. Those who received sacituzumab govitecan and had H-scores of up to 10, between 10 and 100, and at least 100 had overall response rates of 24%, 18%, and 23%, respectively. The safety profile of sacituzumab govitecan by Trop-2 H-score appeared to be congruent with previous reports.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.